| Assay ID | Title | Year | Journal | Article |
|---|
| AID156282 | In vitro binding affinity was tested towards human Peroxisome proliferator activated receptor alpha | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists. |
| AID238856 | Binding affinity for human peroxisome proliferator activated receptor alpha | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID600728 | Displacement of radio-labeled full agonist from PPARgamma receptor | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
| Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling. |
| AID241668 | Inhibition of Peroxisome proliferator activated receptor gamma binding | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
| Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma. |
| AID11226 | Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID238857 | Binding affinity for human peroxisome proliferator activated receptor gamma | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID156145 | In vitro transcriptional activation in COS cells expressing human peroxisome proliferator activated receptor alpha PPAR-GAL4 chimera | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID156941 | In vitro transactivation of human peroxisome proliferator activated receptor gamma measured in PPAR-GAL4 chimeric COS-1 cells | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID156612 | In vitro transactivation of human Peroxisome proliferator activated receptor delta measured in PPAR-GAL4 chimeric COS-1 cells | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID156953 | In vitro binding affinity against human peroxisome proliferator activated receptor gamma | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID240313 | Effective concentration against human peroxisome proliferator activated receptor gamma in Gal4 transactivation assay | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID240312 | Effective concentration against human peroxisome proliferator activated receptor alpha in Gal4 transactivation assay | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID12957 | Bioavailability in fasted male administration of 2 mg/Kg of compound p.o. | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID156772 | In vitro binding affinity was tested towards human Peroxisome proliferator activated receptor delta | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists. |
| AID156954 | In vitro binding affinity against human peroxisome proliferator activated receptor gamma | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists. |
| AID113923 | In vivo efficacy as percent glucose correction in male db/db mice at 10 mg/kg oral dose | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID11908 | Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID123420 | In vivo efficacy as percent triglyceride correction in male db/db mice at 10 mg/kg oral dose | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID156152 | In vitro binding affinity against human Peroxisome proliferator activated receptor alpha | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID156135 | In vitro activity in human Peroxisome proliferator activated receptor alpha-transactivation assay | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists. |
| AID156935 | In vitro activity in human peroxisome proliferator activated receptor gamma-transactivation assay | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists. |
| AID243175 | Calculated inhibitory concentration against Peroxisome proliferator activated receptor dual model as sum of pIC50s for PPARalpha and PPARgamma | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
| Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma. |
| AID156629 | In vitro binding affinity against human Peroxisome proliferator activated receptor delta | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID156609 | In vitro activity in human Peroxisome proliferator activated receptor delta-transactivation assay | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
| Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists. |
| AID12665 | Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v. | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
| 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. |
| AID241667 | Inhibition of Peroxisome proliferator activated receptor alpha binding | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
| Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma. |
| AID1346800 | Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors) | 2004 | Endocrinology, Apr, Volume: 145, Issue:4
| A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. |
| AID1346733 | Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors) | 2004 | Endocrinology, Apr, Volume: 145, Issue:4
| A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |